Delafloxacin: A Review in Community-Acquired Pneumonia

被引:15
作者
Lee, Arnold [1 ]
Lamb, Yvette N. [1 ]
Shirley, Matt [1 ]
机构
[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand
关键词
IN-VITRO ACTIVITY; STREPTOCOCCUS-PNEUMONIAE; STAPHYLOCOCCUS-AUREUS; ADULTS;
D O I
10.1007/s40265-022-01725-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Delafloxacin (BAXDELA (R) in the USA; Quofenix (R) in the EU) is an anionic fluoroquinolone antibacterial that is approved for the treatment of community-acquired pneumonia (CAP) and acute bacterial skin and skin structure infections in adults. Delafloxacin demonstrated in vitro activity against Gram-positive and Gram-negative pathogens, including drug-resistant isolates. In a phase III trial in adults with CAP, delafloxacin was noninferior to moxifloxacin when assessed against FDA- and EMA-defined primary endpoints, with both fluoroquinolones achieving high treatment success rates. A prespecified subgroup analysis suggested that delafloxacin may be more efficacious than moxifloxacin in patients with a history of asthma or chronic obstructive pulmonary disease (COPD). Delafloxacin was generally well tolerated in patients with CAP, with most treatment-emergent adverse events graded as mild or moderate in severity. Fluoroquinolone-associated adverse events of special interest occurred infrequently, with no events of QT prolongation or phototoxicity reported with delafloxacin. Delafloxacin is an effective and generally well-tolerated treatment that increases the number of available treatments for CAP and, although further research is required, may be a useful option for patients with CAP and comorbid asthma or COPD.
引用
收藏
页码:913 / 923
页数:11
相关论文
共 50 条
[41]   Pneumococcal vaccines and the prevention of community-acquired pneumonia [J].
Esposito, Susanna ;
Principi, Nicola .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2015, 32 :124-129
[42]   Community-acquired and hospital-acquired pneumonia [J].
Hauptmeier, B. M. ;
Rohde, G. G. U. .
PNEUMOLOGE, 2013, 10 (05) :351-363
[43]   Immunomodulatory agents in the treatment of community-acquired pneumonia: A systematic review [J].
Corrales-Medina, Vicente F. ;
Musher, Daniel M. .
JOURNAL OF INFECTION, 2011, 63 (03) :187-199
[44]   New antibiotics for community-acquired pneumonia [J].
Kollef, Marin H. ;
Betthauser, Kevin D. .
CURRENT OPINION IN INFECTIOUS DISEASES, 2019, 32 (02) :169-175
[45]   Fluoroquinolones in the management of community-acquired pneumonia [J].
Albertson, T. E. ;
Dean, N. C. ;
El Solh, A. A. ;
Gotfried, M. H. ;
Kaplan, C. ;
Niederman, M. S. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (03) :378-388
[46]   Community-Acquired Pneumonia in Latin America [J].
Iannella, Hernan A. ;
Luna, Carlos M. .
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 37 (06) :868-875
[47]   RHABDOMYOLYSIS ASSOCIATED WITH COMMUNITY-ACQUIRED PNEUMONIA [J].
CARON, F ;
ROBERT, R ;
BADIA, P ;
MALIN, F ;
BERKELMANS, F ;
ROUSSEL, V .
REVUE DE MEDECINE INTERNE, 1994, 15 (04) :240-243
[48]   Guidelines to Manage Community-Acquired Pneumonia [J].
Wunderink, Richard G. .
CLINICS IN CHEST MEDICINE, 2018, 39 (04) :723-+
[49]   Community-acquired pneumonia: is less more? [J].
Peghin, Maddalena ;
Bouza, Emilio .
LANCET INFECTIOUS DISEASES, 2022, 22 (02) :159-161
[50]   Antibiotics for community-acquired pneumonia in children [J].
Kabra, Sushil K. ;
Lodha, Rakesh ;
Pandey, Ravindra M. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (03)